Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

By sjmartinez • August 31, 2023

Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 Aug;11(8):e007118. doi: 10.1136/jitc-2023-007118. PMID: 37648261; PMCID: PMC10471850.

Tags: Cell Engineering, Cellular, cytotoxicity, Hematologic Neoplasms, Hematology/Oncology, immunity, Immunologic, immunotherapy, Publications

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair

Hollowed J, Woo H, Hamburg S, Ardehali A. Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair. Tex Heart Inst J. 2025 Jul[...]

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]